
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Fourteen of 3,304 lovastatin recipients developed melanoma during five years of follow-up, compared to 27 of 3,301 placebo patients






